LEXINGTON, Mass., June 11, 2015 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (Nasdaq: TTOO ), a company developing innovative diagnostic products to improve patient health, today announced that members of its management team are scheduled to participate in several discussion panels at the 2015 BIO International Convention, the world's largest annual gathering of the biotechnology industry. The convention is being held June 15-18, 2015 in Philadelphia, Pennsylvania at the Pennsylvania Convention Center.
Members of the company's management are scheduled to participate in the following discussion panels:
| Title: | Transforming Diagnostics With Innovative Technologies: Potential and Pitfalls |
| Date & Time: | Wednesday, June 17, 2015, 2:00-3:15 p.m. EDT |
| Session: | Breakout Session – Personalized Medicine & Diagnostics |
| Location: | Room 105AB |
| Moderator: | Jo Natauri, partner, Goldman Sachs |
| Speakers: | John McDonough, president and CEO, T2 Biosystems |
| Don Hardison, president and CEO, Good Start Genetics | |
| Michael Pellini, M.D., CEO, Foundation Medicine | |
| Title: | Circling the Wagons: Can Vaccines, Diagnostics, and Novel Products Make Antibiotics Better? |
| Date & Time: | Thursday, June 18, 2015, 1:00-2:15 p.m. EDT |
| Session: | Breakout Session – Infectious Diseases |
| Location: | Room 113A |
| Moderator: | Bruce Gellin, director, National Vaccine Program Office, HHS |
| Speakers: | Tom Lowery, Ph.D., CSO, T2 Biosystems |
| Tim Cooke, Ph.D., CEO, Novadigm | |
| Charles Knirsch, M.D., MPH, vice president, Vaccines Clinical Research, Pfizer | |
| Florence Sejourne, CEO, Da Volterra |
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to bring such products to market. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 4, 2015, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.
Media Contact: Dan Budwick, Pure Communications 973-271-6085 Investor Contact: Matt Clawson, Pure Communications 949-370-8500
